CVS will stop selling important Prostate Cancer drug in two months

Submitted by Matt on Thu, 2016-11-03 23:46

From Malecare.org:

CVS Pharmacy is hurting millions of cancer patients by refusing to sell dozens of cancer treatment drugs, like leukemia drug Tasigna, prostate cancer drug Xtandi and chemotherapy treatment drug Neupogen, starting in 2017. CVS claims these drugs cost too much. Go ahead and tell that to my insurance provider and Medicare but don't stop selling these drugs to me and millions of cancer patients.

CVS is putting profit above the care of cancer patients.  If CVS can make money by selling cheap cosmetics and imported cookies, then CVS can make money off of lifesaving drugs. 

CVS says there are other drugs that work just as well for most patients. But "most" is not "all patients." That's why doctors prescribe different drugs to different patients.

CVS Pharmacy is currently the largest pharmacy chain in the United States. For millions of American's, CVS is the only pharmacy for miles around. By hurting millions of cancer patients, CVS has become a face of evil. Now, it's up to us to make phone calls, write letters or send emails to change the course of this wrongheaded move. 

Tell CVS' Medical Director to sell all FDA approved cancer drugs, not just the ones that give CVS the most profit:

Send your email to:

troyen.brennan@cvshealth.com

You can also telephone him at:
401-770-4801 and 401-651-3137

Troyen Brennan, MD, MPH 
Chief Medical Director 
CVS Health 
One CVS Drive 
Woonsocket, Rhode Island 02895

Please feel encouraged to share your comments with me.

Darryl Mitteldorf, LCSW

Executive Director
Malecare
darryl@malecare.org

Like0 Dislike0

Comments

A bit strong. More like just another example of profits put over people. But alas such is the way of the wicked world.

Now, that guy who jacked up that one cancer drug by what, 7000%? THAT dude definitely has evil going on in his being. But this? Well yes, very distasteful. But pure evil? A bit much.

Still, I get the idea. CVS needs to hear the objections.

Like0 Dislike0
Submitted by Matt on Thu, 2016-11-03 23:53